Marina C. Garassino, MD

Videos

Closing out her discussion on PD-L1–high metastatic NSCLC, Marina Chiara Garassino, MD, looks toward future evolutions in the treatment paradigm.

PD-L1–High Advanced NSCLC: Future Directions in Care 

Centering focus on the second-line setting of PD-L1–high metastatic NSCLC, a key opinion leader defines a potential role for chemoimmunotherapy,

Potential Role for Chemoimmunotherapy in the 2L Setting of PD-L1–High Advanced NSCLC

Highlighting data from the EMPOWER-Lung1 trial, Marina Chiara Garassino, MD, considers the role of first-line cemiplimab in managing PD-L1–high metastatic NSCLC.

EMPOWER-Lung1: First-Line Cemiplimab Use in PD-L1–High Advanced NSCLC

Comprehensive insight to factors that inform the optimal selection of first-line therapy for patients with PD-L1–high metastatic non–small cell lung cancer. 

Factors in Selecting First-Line Therapy for PD-L1–High Metastatic NSCLC 

Expert oncologist Marina Chiara Garassino, MD, reflects on a patient case of PD-L1–high metastatic NSCLC and outlines first-line treatment options in this setting.

A Patient Case of PD-L1–High Metastatic NSCLC: First-Line Treatment Options 

Marina C. Garassino, MD, medical consultant, Thoracic Unit, Fondazione IRCCS  Istituto Nazionale dei Tumori, Milan, Italy, discusses the results from the randomized phase III RELAY trial, in which the combination of ramucirumab (Cyramza) plus erlotinib (Tarceva) was compared to erlotinib plus placebo in patients with EGFR-mutated non&ndash;small cell lung cancer (NSCLC). These data were presented at the 2019 ASCO Annual Meeting.

Overall, the median progression-free survival (PFS) was 19.4 months by investigator assessment in the ramucirumab/erlotinib arm versus 12.4 months in the erlotinib-alone arm (HR, 0.591; 95% CI, 0.461-0.760; P <.0001). Garassino says it is still early for the overall survival data as they have not yet matured, but the results suggest that the PFS2 is longer in the combination arm as well. She also notes that the toxicity profile was manageable with the combination regimen.

Marina C. Garassino, MD, medical consultant, Thoracic Unit, Fondazione IRCCS &ndash; Istituto Nazionale dei Tumori, Milan, Italy, discusses the results from the randomized phase III RELAY trial, in which the combination of ramucirumab plus erlotinib was compared to erlotinib plus placebo in patients with EGFR-mutated non&ndash;small cell lung cancer. These data were presented at the 2019 ASCO Annual Meeting.

Marina C. Garassino, MD | Authors

Articles

PD-L1–High Advanced NSCLC: Future Directions in Care

Potential Role for Chemoimmunotherapy in the 2L Setting of PD-L1–High Advanced NSCLC

EMPOWER-Lung1: First-Line Cemiplimab Use in PD-L1–High Advanced NSCLC

Factors in Selecting First-Line Therapy for PD-L1–High Metastatic NSCLC

A Patient Case of PD-L1–High Metastatic NSCLC: First-Line Treatment Options

Interpreting the Role of the Ramucirumab Plus Erlotinib Combination in EGFR+ NSCLC